Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link 
Samsung Launches Galaxy Z TriFold to Elevate Its Position in the Foldable Smartphone Market 
Senators Warn Trump Against Unauthorized Venezuela Strike, Vow War Powers Push 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Cuba Reaffirms Anti-Drug Cooperation as Tensions Rise in the Caribbean 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
UN Chief Says Gaza Operation “Fundamentally Wrong” as Concerns Over War Crimes Grow 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
U.S. Repatriation Flight Carrying 266 Venezuelan Migrants Lands in Caracas 
California Launches Portal for Reporting Alleged Misconduct by Federal Immigration Agents 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Trump Administration Plans Major Rollback of Biden-Era Fuel Economy Standards 
Australia Progresses AUKUS Review as U.S. Affirms Strong Support 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
